Hydromer Inc. and N8 Medical, LLC have entered into a Supply and Support Agreement. Under the terms of this agreement, both parties will work together to jointly create and commercialize new antimicrobial coatings for the medical device market. The parties seek to capitalize on Hydromer's leadership in medical grade polymeric coating technology in combination with N8 Medical's novel class of compounds known as Ceragenins or CSAs. Ceragenins are patented synthetic peptidomimetic compounds licensed from Brigham Young University by N8 Medical that mimic the polyfunctional and broad spectrum activity of a key component of the human innate immune system. This new Ceragenin technology is targeted at combating hospital-acquired infections (HAIs).